Micro-Raman spectroscopy, integrated with statistical analysis, discriminates CLL prognostic groups, revealing biochemical heterogeneity beyond conventional molecular markers. The method identifies ...

Targeted therapies may improve survival in these patients by concurrently managing immune dysregulation and the leukemic clone.

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...

Genomic complexity was defined by CNA burden, with ≥3 alterations indicating complexity and ≥5 indicating high genomic complexity, reflecting karyotypic and copy-number disruption rather than single ...

In chronic lymphocytic leukemia (CLL), certain recurrent genetic alterations are known to influence disease progression and survival. One important abnormality is the loss of part of chromosome 11, ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Caregivers play a crucial role in helping Chronic Lymphocytic Leukemia (CLL) patients manage the emotional side of a chronic ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...

Medically reviewed by Archana Sharma, DO Key Takeaways Active surveillance, or watchful waiting, is often recommended for people with slow-growing CLL who do not have symptoms.Targeted therapies, such ...

Follicular lymphoma is a chronic, incurable blood cancer requiring regular monitoring, even during remission. Blood work is routine, but CT scans can trigger anxiety due to their role in initial ...

Secondary infections are those that develop because CLL or its treatment weakens your immune system, reducing your body’s ability to fight bacteria, viruses, and fungi, says Wade Swenson II, MD, a ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...